Advertisement

Topics

Search Results for "New Treatment For Hepatitis B"

17:21 EDT 24th May 2017 | BioPortfolio

Matching Channels

Hepatitis B

Hepatitis A

Hepatitis C

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV R...

Hepatitis E virus HEV

Hepatitis B virus HBV

Matching News

Specific genotype may predict recovery in patients with advanced cirrhosis after hepatitis c treatment

Genotyping of patients with advanced cirrhosis from hepatitis C virus could help health-care professionals predict the likelihood of improvement after successful hepatitis C treatment, thus minimizing...

Hepatitis C Treatment: Issues for the Emergency Physician

This issue is written to provide you with the knowledge to be able to ask and educate patients with hepatitis C about the highly effective treatment available for most all infected patients.

AbbVie's hepatitis C treatment under accelerated review by EMA

The European Medicines Agency (EMA) has validated AbbVie's marketing authorization application (MAA) for a new hepatitis C treatment.

World Hepatitis summit

(World Hepatitis Alliance) Worldwide, viral hepatitis kills more than one million people each year, and up to 400 million people are chronically infected with hepatitis B or C. Yet there has never bee...

EMA Accelerated Assessment for AbbVie's hepatitis C regimen

AbbVie has announced that its investigational, pan-genotypic regimen of Glecaprevir/Pibrentasvir has been awarded Accelerated Assessment by the European Medicines Agency (EMA) for the treatment of all...

Treating Hepatitis C Can Reactivate Hepatitis B

Direct-acting antivirals for hepatitis C may cause recrudescence of hepatitis B and lead to mortality in co-infected patients.

New interferon shows promise against hepatitis B in cell culture, and animal model

Hepatitis B is notoriously difficult to eradicate with currently available agents.. Now, in a new study, a novel form of "pegylated" interferon-β has reduced hepatitis B virus (HBV) infections in exp...

New hepatitis data highlight need for urgent global response

New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicate...

Matching PubMed Articles

Antiviral treatment and liver-related complications in hepatitis delta.

Hepatitis delta is the most severe form of viral hepatitis. Pegylated interferon alfa (PEG- IFNα) is effective in only 25-30% of patients and is associated with frequent side effects. The aim of this...

Update on Hepatitis C treatment: Systematic review of clinical trials.

Chronic Hepatitis C is a major public health problem. The chronicity of the Hepatitis C can lead to advanced liver disease, cirrhosis and even hepatocellular carcinoma. Chronic hepatitis C is the lead...

On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B.

To investigate potential predictors for treatment response to nucleos(t)ide analogues (NAs) in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients.

Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.

Previous studies have revealed that hepatitis B core antibody (anti-HBc) levels vary throughout the different phases of treatment-naïve chronic hepatitis B (CHB) patients and can be used as a predict...

Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach.

Hepatitis C is an infectious liver disease with high mortality rate which is caused by Hepatitis C virus. Several treatment methods have been applied to combat this deadly virus including interferons,...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement